Proceedings of the 2013 annual meeting of the Netherlands Epidemiology Society
Volume 1 Issue S1 Abstract 10
Jannie van der Helm, Public Health Service Amsterdam, Amsterdam, the Netherlands
Daan Geraets, DDL Diagnostic Laboratory, Rijswijk, the Netherlands
Antoon Grunberg, Dept. of Public Health Ministry of Health Suriname
Koen Quint, Department of dermatology LUMC, University of Leiden, Leiden, the Netherlands
Leslie Sabajo, Dermatological Service, Ministry of Health, Paramaribo, Suriname
Henry de Vries, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Cervical cancer is caused by high-risk (HR) Human Papilloma Virus (HPV) infections. Current HPV vaccinations protect against cancers induced by HR-HPV 16 and -18, and are not yet available in Suriname. We estimated prevalence and risk factors for urogenital HR-HPV infections among women from five major ethnic groups in Paramaribo, Suriname in a pre- vaccination era.
Between July 2009 and February 2010, women aged ≥18 years were recruited at two clinics. Vaginal swabs were collected and HPV detection was performed using the SPF10 PCR and DNA enzyme immunoassay (DEIA). DEIA-positive samples were genotyped by LiPA25 reverse hybridization assay, targeting 25 different genotypes. Logistic regression analysis was used
to identify determinants of HPV infection.
1001 women were tested for HPV of whom 584 (58%) were DEIA positive. Of the positive samples 472 (81%) could be typed by LiPA25. HR-HPV types were detected in 303 (30%) of all samples. HPV type 52 was the most prevalent genotype (n=79; 8%). Of the HR-HPV, 46 (15%) had only HR-HPV types 16 and/or 18. Age, ≥2 recent partners, Chlamydia trachomatis co-infection and ethnic group (OR=2.1, 95%CI=1.4-3.1 for Creole; OR=2.0, 95%CI=1.2-3.3 for Maroon; OR=2.8, 95%CI=1.8-4.4 for Mixed race compared to Hindustani) were significantly associated with HR-HPV in multivariable analyses.
HR-HPV is not equally distributed among ethnic groups. 85% of HR-HPV infections involve types that are not covered by the 2 currently available vaccines against cervical cancer. These data provide a basis for possible shifts in HPV genotype prevalence following vaccination.
Published: 06 Jun, 2013